Emily Leproust

What if life-saving drugs could be brewed like beer?

What if data could be stored not in hard drives, but in DNA?

In 2013, after 13 years at Agilent, Emily left to start Twist Bioscience.

Her goal? Disrupt gene synthesis by writing DNA on silicon chips.

The result? Faster, cheaper access to synthetic DNA for everything from mRNA vaccines to spider silk.

Her company powers breakthroughs in agriculture, biomedicine, even data storage.

But the science wasn’t the only thing under a microscope…
Agilent sued. A $22.5M settlement followed.

Short sellers issued a 236-page takedown accusing her of fraud.

A class action lawsuit came next.

But she hasn’t flinched.

With over 30 peer-reviewed papers, dozens of patents, and awards like the Rosalind Franklin Leadership Prize, Emily is still leading the charge.

You’ve probably never heard her name, but your future might depend on her work.